Kestra Medical Technologies Inc (KMTS) shares plummeted 12.47% in after-hours trading following the release of its Q2 FY26 financial results. The company reported a loss of $0.64 per share, missing the analyst consensus estimate of a $0.59 loss.

Despite revenue of $22.565 million (up 53% YoY) beating estimates of $20.7 million and raised FY26 revenue guidance to $91 million, investors focused on the widening net loss of $32.8 million compared to $20.6 million in the prior year period. The EPS miss and increased operating expenses ($43.2 million vs. $25.0 million YoY) drove the negative market reaction.